The Trump administration says it will examine whether Germany’s reimbursement practices constitute “persistent underpayment” for new drugs or “burden or restrict US commerce.”
The United States has launched a formal trade investigation into Germany’s proposed drugâspending reforms, escalating concerns that the country’s pricing policies may undervalue innovative medicines and disadvantage US pharmaceutical companies.
The Office of the United States Trade Representative (USTR) announced the Section 301 probe last week, saying it
Read more articles like this one with our free plan, or get our Premium plan for access to all content – including our 5,000+ article archive, exclusive interviews, podcasts, and more.
